Compare LMNR & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMNR | ADAG |
|---|---|---|
| Founded | 1893 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.9M | 254.4M |
| IPO Year | 2005 | 2020 |
| Metric | LMNR | ADAG |
|---|---|---|
| Price | $12.69 | $3.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $20.00 | $8.25 |
| AVG Volume (30 Days) | 53.7K | ★ 93.6K |
| Earning Date | 06-08-2026 | 04-01-2026 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $159,723,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.20 | $1.44 |
| 52 Week High | $17.11 | $4.75 |
| Indicator | LMNR | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 49.71 |
| Support Level | $12.54 | $3.35 |
| Resistance Level | $14.86 | $3.99 |
| Average True Range (ATR) | 0.36 | 0.33 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 2.53 | 62.20 |
Limoneira Co is predominantly an agribusiness company. Its current operations consist of fruit production and marketing, rental operations, real estate, and capital investment activities. The company has three business divisions; agribusiness, rental operations, and real estate development. The agribusiness division which accounts for a majority of the firm's revenue represents its core operations of farming, harvesting, lemon packing, and lemon sales operations. The company's reportable operating segments are fresh lemons, lemon packing, avocados, and other agribusiness, which predominantly includes oranges, specialty citrus, other crops, and farm management services. A majority of its revenue is derived from the Fresh Lemons segment.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.